NCT03275363

The University of Hong Kong Neurocognitive Disorder Cohort

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational study of older HK Chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment.

Detailed description

The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational study of older HK Chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment, and in particular the biomarkers that predict cognitive and functional decline. Comprehensive profiling of each subject is performed through a multi-domain assessment protocol including detailed demographics, lifestyle factors, neuropsychological battery, mood, MRI, genetics, blood biomarkers, and other patient-centred parameters including level of disability, quality of life and societal engagement. Ongoing annual follow up captures the essential clinical events and changes in neurocognitive function (conversion to MCI or dementia), mood, level of disability and quality of life; as well as repeat blood tests. The HKU NCD Cohort is the first-ever Asian dementia cohort to be formally included into the Dementia Platforms UK, achieving an international collaborative status with other UK-based cohorts. The study neuropsychological battery is aligned with the NACC UDS3 battery.

Conditions

• Neurocognitive Disorder
• Mild Cognitive Impairment
• Alzheimer Dementia
• Vascular Dementia
• Age-related Cognitive Decline

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Neurocognitive battery	Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted). NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span.
DIAGNOSTIC_TEST	MRI	MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
BIOLOGICAL	Blood tests	Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
DIAGNOSTIC_TEST	EEG with event-related potential (ERP)	128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
DIAGNOSTIC_TEST	Amyloid PET CT	F18 Flutametamol PET CT for selected patients

Timeline

• Start date: 2014-09-01
• Primary completion: 2022-01-01
• Completion: 2022-01-04
• First posted: 2017-09-07
• Last updated: 2017-09-07

Locations

1 site across 1 country: Hong Kong